KemPharm Announces Positive Topline Data from Phase 1 Clinical Trial Evaluating Cardiovascular Safety of Serdexmethylphenidate (SDX)

2 years ago

SDX administered at single doses of 80 mg and 200 mg was well-tolerated CELEBRATION, Fla., Sept. 28, 2022 (GLOBE NEWSWIRE)…

ReWalk Takes Another Step Toward Medicare Coverage

2 years ago

ReWalk to submit first cases for Medicare coverage through Medicare Administrative Contractors (MACs)Centers for Medicare and Medicaid Services (CMS) affirms…

Resverlogix Confirms Focus on Treatment of Post COVID-19 Conditions

2 years ago

CALGARY, Alberta, Sept. 28, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix" or the “Company”) (TSX:RVX) today announced that apabetalone’s future…

OraSure Technologies Receives $8.6 Million BARDA Contract to Develop 2nd Generation Ebola Test

2 years ago

BETHLEHEM, Pa., Sept. 28, 2022 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a global leader in point-of-care and home…

Mainz Biomed Strengthens Board of Directors with Nomination of Dr. Heiner Dreismann and Gregory Tibbitts

2 years ago

Dr. Dreismann, Former Roche Molecular Diagnostics CEO, and Mr. Tibbitts, a Highly-accomplished Life-Sciences Executive, Provide Extensive Experience in Diagnostics and…

KBio Announces Strategic Collaboration with Leaf Expression Systems to Enhance Development and Production of Novel Therapeutics

2 years ago

Collaboration to focus on new plant lines and other plant-based technologies aimed at efficient production scale-up of KBio's current and…

Cara Therapeutics Announces Difelikefalin (KORSUVA®) Injection New Drug Application Has Been Submitted in Japan

2 years ago

STAMFORD, Conn., Sept. 28, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment…

Cornerstone Pharmaceuticals Initiates Phase 1 Trial of CPI-613® (devimistat) in Combination with Chemoradiation for the Treatment of Advanced Pancreatic Cancer

2 years ago

Clinical program advancement represents key milestone for Cornerstone underscoring its commitment to the development of lead compound, devimistat, in pancreatic…

Microbix Announces Initiation of Normal Course Issuer Bid

2 years ago

Microbix to Repurchase up to 5% of its outstanding shares over 12 monthsMISSISSAUGA, Ontario, Sept. 28, 2022 (GLOBE NEWSWIRE) --…

First Wave BioPharma’s CEO James Sapirstein to Present at Inaugural Roth Healthcare Opportunities Conference

2 years ago

BOCA RATON, Fla., Sept. 28, 2022 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ: FWBI), (“First Wave BioPharma” or the…